CClinicalTrials.gg
CompletedNCT05143008Updated Dec 3, 2021

A Pilot Study to Evaluate an Intervention for Gestational Weight Gain

An interventional study of SMART Intervention in Pregnancy Related, Weight Gain and Maternal, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to female participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2021-12-03.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 3 months after the study started (first participant enrolled Aug 2015, registered Nov 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
14 Years and older
Sex
Female
01

Study summary

The purpose of this study is to enable the investigator to conduct proof of concept work related to the feasibility, acceptability, initial efficacy and mechanisms of action (focusing on maternal and infant modifiable factors) for a novel self-management intervention for pregnant women.

Read the detailed description

This proposed study aims to adapt intervention to address excessive gestational weight gain and psychosocial functioning among a socioeconomically and racially diverse sample of pregnant women .Additionally, data on behavioral mechanisms associated with self-regulatory capacity, such as impulsive control and the ability to delay rewards, that may be linked to self-regulation during pregnancy are needed to support future interventions.

In this study, the investigators will develop and adapt an intervention (Self-Management Around the Reproductive Transition; SMART) that addresses maternal weight, stress, and mood, and document the feasibility, acceptability and initial efficacy of the SMART intervention.

02

Conditions studied

  • Pregnancy Related
  • Weight Gain
  • Maternal

Browse trials for

03

In context

Weight Gain

405 studies on the registry are indexed under Weight Gain; 52 are open to participants now.

This study's enrollment of 15 is below the median of 83 across 324 interventional studies indexed under Weight Gain.

Browse Weight Gain studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,385 studies on the registry; 167 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • At least 14 years of age
  • Less than 16 weeks gestation
  • English speaking
  • Singleton pregnancy
  • Receiving care at Magee-Womens Hospital, Latterman family health or other UPMC practices that provide obstetric care

Exclusion criteria

Exclusion Criteria:

  • Preexisting diabetes
  • Use of medications known to affect weight
  • Enrolled in current weight management programming
  • History of weight loss surgery
  • Women who endorse acute psychiatric symptoms (e.g., suicidality) that warrant immediate care
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    SMART Intervention

    Counseling sessions will be completed with a toolbox approach so that clinicians can work on topics that are of interest and relevant to each participant. SMART will focus on weight, physical activity, eating and psychosocial issues. Intervention goals will emphasize adherence to healthy behaviors rather than absolute weight goals. Specifically, women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.

    Behavioral: SMART Intervention

Interventions

  • BehavioralSMART Intervention

    Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.

06

What researchers measure

Primary outcomes

  1. Number of sessions attended among women enrolled in the study

    Number of sessions attended will be calculated for each participant

    Time frame: Approximately 9 months

  2. Number of self-monitoring forms returned

    Number of self-monitoring forms returned will be calculated for each participant

    Time frame: Approximately 9 months

  3. Gestational weight gain

    Gestational weight gain will be calculated for each participant. Weight in pounds will be measured on a calibrated scale while women are in street clothes without shoes.

    Time frame: Approximately 9 months

Secondary outcomes

  1. Depressive symptoms

    The Center for Epidemiological Studies-Depression Scale will be used to assess depressive symptomatology. A total scores is calculated by finding the sum of the 20 items. Total scores range from 0-60, with higher scores reflecting greater depressive symptomatology.

    Time frame: Approximately 12 months

  2. Perceived stress symptoms

    The Perceived Stress Scale will be administered to measure symptoms of perceived stress. The Perceived Stress Scale score is obtained by summing the points awarded to the 10 items and it ranges from 0 to 40. Higher scores indicate greater perceived stress.

    Time frame: Approximately 12 months

07

Study locations

1 site
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05143008
Lead sponsor
University of Pittsburgh
Responsible party
Michele Levine (Associate Professor, University of Pittsburgh) — Principal investigator
First posted
Dec 3, 2021
Start date
Aug 13, 2015
Primary completion
Feb 19, 2017
Completion
Feb 19, 2017
Last update
Dec 3, 2021

Study contacts

Michele Levine, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion